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Abstract 1 
Nitric oxide (NO), is a neurotransmitter synthesised in the brain by neuronal nitric oxide synthase 2 
(nNOS). Using immunohistochemistry and confocal imaging in the inferior colliculus (IC, auditory 3 
midbrain) of the guinea pig (Cavia porcellus, male and female), we show that nNOS occurs in two 4 
distinct cellular distributions. We confirm that in the cortices of the IC, a subset of neurons show 5 
cytoplasmic labelling for nNOS, while in the central nucleus (ICC) such neurons are not present. 6 
However, we demonstrate that all neurons in the ICC do in fact express nNOS in the form of discrete 7 
puncta found at the cell membrane.  Our multi-labelling studies reveal that nNOS puncta form multi-8 
protein complexes with NMDA receptors, soluble guanylyl cyclase (sGC), and PSD95.  These 9 
complexes are found apposed to glutamatergic terminals indicative of synaptic function. 10 
Interestingly, these glutamatergic terminals express both vesicular glutamate transporters 1 and 2 11 
denoting a specific source of brainstem inputs. With in vivo electrophysiological recordings of 12 
multiunit activity in the ICC, we found that local application of NMDA enhances sound-driven activity 13 
in a concentration-dependent and reversible fashion. This response is abolished by blockade of 14 
nNOS or sGC indicating that the NMDA effect is mediated solely via the NO and cGMP signalling 15 
pathway. This discovery of a ubiquitous, but highly localised expression, of nNOS throughout the ICC 16 
and demonstration of the dramatic influence of the NMDA activated NO pathway on sound-driven 17 
neuronal activity, imply a key role for NO signalling in auditory processing.  18 
  
3 
Significance statement  19 
We show that nNOS, the enzyme that synthesises nitric oxide (NO), occurs as puncta in apparently 20 
all neurons in the central nucleus of the inferior colliculus (ICC) in the auditory midbrain. Punctate 21 
nNOS appears at glutamatergic synapses in a complex with glutamate NMDA receptors, soluble 22 
guanylyl cyclase (the NO receptor), and PSD-95 (a protein that anchors receptors and enzymes at the 23 
postsynaptic density). We show that NMDA-receptor modulation of sound-driven activity in the ICC 24 
is solely mediated by activation of nNOS and soluble guanylyl cyclase. The presence of nNOS 25 
throughout this sensory nucleus, argues for a major role of NO in hearing. Furthermore, this 26 
punctate form of nNOS expression may exist and have gone unnoticed in other brain regions.   27 
  28 
4 
Introduction 29 
Nitric oxide (NO) is a signalling molecule in diverse life-forms (Feelisch and Martin, 1995; Moroz and 30 
Kohn, 2011). In the brain, NO is produced through the action of the calcium/calmodulin-dependent 31 
enzyme nNOS, and is involved in intra- and inter-cellular signalling in neurons and glia (Garthwaite, 32 
2008; Garthwaite, 2016). NO can act within the cell in which it is produced, or it may diffuse across 33 
the cell membrane to act in presynaptic terminals, or, by volume transmission, at more distant sites 34 
(O'Dell et al., 1991; Steinert et al., 2008; Hardingham et al., 2013; Bellefontaine et al., 2014; 35 
Garthwaite, 2016). 36 
Several studies have shown a functional interaction between glutamate NMDA-receptor activation, 37 
nNOS, and soluble guanylyl cyclase (sGC) -the enzyme catalysing the production of cGMP. Calcium 38 
ions (Ca2+) entering through the NMDA receptor (Garthwaite et al., 1988) activate nNOS and the NO 39 
produced activates sGC (Arnold et al., 1977) leading to increased levels of cGMP.  40 
The functional coupling of the NMDA receptor, nNOS, and sGC suggests they should be in close 41 
proximity at glutamatergic synapses so that small intracellular changes in Ca2+ can activate nNOS and 42 
allow the NO produced to activate its main downstream receptor sGC (Garthwaite, 2008). Several 43 
studies have shown that nNOS binds to a scaffolding protein, postsynaptic density protein (PSD) 95 44 
(Brenman et al., 1996). This protein also anchors the NMDA receptor at the postsynaptic membrane 45 
(Valtschanoff and Weinberg, 2001; Burette et al., 2002). Furthermore, an isoform of soluble guanylyl 46 
cyclase has been shown to bind to PSD95 in brain homogenates (Russwurm et al., 2001). Thus far, 47 
however, the four proteins (PSD95, the NMDA receptor, nNOS and sSG) have not been shown to 48 
exist as a single complex in native tissue.  49 
Most studies exploring NO signalling in the brain have been in hippocampus, cerebellum, and cortex 50 
(Garthwaite et al., 1988; Shibuki and Okada, 1991; Hardingham and Fox, 2006). However, nNOS 51 
occurs in many other brain regions including those associated with sensory processing. Despite the 52 
presence of nNOS in sensory systems, with a few exceptions (Cudeiro et al., 1994; Steinert et al., 53 
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2008; Steinert et al., 2011; Lima et al., 2014; Yassin et al., 2014; Kopp-Scheinpflug et al., 2015) 54 
relatively little attention has been given to the role of NO in such regions. One sensory structure 55 
expressing particularly high levels of nNOS is the inferior colliculus (IC) (Endoh et al., 1994). This 56 
principal midbrain centre of the auditory pathway processes virtually all ascending auditory 57 
information which it integrates with descending projections from the forebrain and non-auditory 58 
inputs (Oliver and Cant, 2018).  59 
The IC consists of three subdivisions. The dorsal and lateral cortices (ICD and ICL) (Faye Lund and 60 
Osen, 1985; Oliver, 2005), contain neurons that express nNOS densely throughout their somata and 61 
dendrites (Herbert et al., 1991; Druga and Syka, 1993; Coote and Rees, 2008). Injection of nNOS 62 
inhibitors into ICD influences sound evoked potentials in the cerebral cortex (Iannone et al., 1996) 63 
suggesting that NO signalling in these neurons has a functional role in sound processing. The third 64 
subdivision is the tonotopically organised central nucleus (ICC). Its primary inputs are ascending 65 
auditory projections from the brainstem, and its output is the main source of input to the higher 66 
auditory system. nNOS filled neurons are absent from the greater part of ICC and occur only at its 67 
border with ICD, suggesting that NO signalling is not a feature of this nucleus (Coote and Rees, 2008).  68 
In contrast to earlier studies, here we report that apparently all neurons in the ICC do contain nNOS, 69 
but that this occurs in a previously undescribed punctate form. We demonstrate that nNOS puncta 70 
co-exist with NMDA receptors, sGC, and PSD95 forming multi-protein signalling complexes, and 71 
these occur in apposition to glutamatergic terminals indicating their synaptic location. We highlight 72 
the functional importance of these synapses by showing that NMDA modulates sound-driven activity 73 
in the ICC in vivo and this response is mediated via nNOS and sGC. 74 
  
6 
Materials and Methods 75 
Animals 76 
Experiments were performed in accordance with the terms and conditions of a license (PPL 60/3934) 77 
issued by the UK Home Office under the Animals (Scientific Procedures) Act 1986, and with the 78 
approval of the Local Ethical Review committee of Newcastle University. Male and female adult 79 
pigmented guinea pigs (Cavia porcellus) were bred in-house and kept in spacious housing conditions 80 
with food and water available ad libitum. Animals were used for experiments between the ages of 81 
40 and 200 days old. 82 
Immunohistochemistry 83 
Tissue collection and preparation 84 
Animals were deeply anaesthetised with pentobarbital and transcardially perfused either with 85 
heparinised 0.1M phosphate buffered saline (PBS) followed by 4% paraformaldehyde (PFA) in PBS, 86 
or with 4% PFA only. The brains were post fixed overnight in 4% PFA, cryoprotected in 30% sucrose, 87 
and stored at -80° C until they were processed. Coronal sections (40 µm) through the IC were cut on 88 
a freezing microtome, and collected into PBS. Sections not immediately required were stored in an 89 
antifreeze solution (30% ethylene glycol, 30% sucrose, 1% polyvinyl pyrrolidone (PVP)-40 in PBS) 90 
(Watson et al., 1986) at -20 °C.  91 
Immunohistochemistry 92 
Sections were washed in PBS (3 x 10 min), incubated in 5 % NaBH4 (20 min) (for antigen retrieval) 93 
and washed again in PBS (3x10 min). Sections were then incubated (overnight at 4 °C) with primary 94 
antibodies diluted in a ‘block buffer’ comprising 0.1 % porcine gelatine (BDH), 1 % bovine serum 95 
albumin (Sigma) in 50 mM glycine (Fisher) in PBS (with or without 0.05-0.1 % Triton-X; Sigma). In 96 
some cases, sections were pre-incubated in block buffer (1-2 h) before addition of the primary 97 
antibodies. The following nNOS antibodies were used: rabbit anti-nNOS (1:2000, Sigma-Aldrich Cat# 98 
N7280, RRID:AB_260796); mouse anti-nNOS (1:250-1:500, Sigma-Aldrich Cat# N2280, 99 
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RRID:AB_260754); sheep anti-nNOS (1:500, Millipore Cat# AB1529, RRID:AB_90743). We established 100 
that all three antibodies resulted in near identical labelling. We also used goat anti-PSD95 (1:1000, 101 
Abcam Cat# ab12093, RRID:AB_298846); rabbit anti-sGC α2β1 subunit (1:1000, Abcam Cat# 102 
ab42108, RRID:AB_732741); mouse anti-GluN1 (NMDA-R subunit) (1:500, Millipore Cat# MAB363, 103 
RRID:AB_94946); goat anti-VGluT1 (1: 500, Synaptic Systems Cat# 135 307, RRID:AB_2619821); 104 
rabbit anti-VGluT2 (1:1000, Synaptic Systems Cat# 135 403, RRID:AB_887883); rabbit anti-VGAT 105 
(1:1000, Synaptic Systems Cat# 131 003, RRID:AB_887869); rabbit anti-Neurochrom™ (PAN) (which 106 
labels somatic, nuclear, dendritic, and axonal neuronal proteins) (1:2000-4000, Millipore Cat# 107 
ABN2300, RRID:AB_10953966); rabbit anti-GABA (1:500-1:1000, Sigma-Aldrich Cat# A2052, 108 
RRID:AB_477652); mouse anti-NeuN (1:1000, Merck  Cat# MAB377, RRID: RRID:AB_2298772).  109 
After overnight incubation, sections were washed (3 x 10 min PBS) and incubated for 2 h with 110 
secondary antibodies diluted in 5% normal goat serum (Vector Labs) in PBS. The following secondary 111 
antibodies were used (all at 1:500 dilution): Alexa Fluor 568 goat anti-rabbit (Thermo Fisher 112 
Scientific Cat# A-11036, RRID:AB_10563566); Alexa Fluor 488 goat anti-mouse (Thermo Fisher 113 
Scientific Cat# A-11029, RRID:AB_2534088); Alexa Fluor 488 chicken anti-rabbit (Thermo Fisher 114 
Scientific Cat# A-21441, RRID:AB_2535859); Alexa Fluor 488 donkey anti-sheep (Thermo Fisher 115 
Scientific Cat# A-11015, RRID:AB_2534082); CY5 donkey anti-goat (Abcam Cat# ab97117, 116 
RRID:AB_10679586); AMCA donkey anti-mouse (Jackson ImmunoResearch Labs Cat# 715-155-151, 117 
RRID:AB_2340807). Sections were washed in PBS (1 x10 min), incubated with the nuclear stain 4', 6-118 
diamidino-2-phenylindole (DAPI, Invitrogen) (10 min, 1-2 nM in PBS), washed in PBS (1 x 10 min) and 119 
finally rinsed in distilled water. Sections were mounted on glass slides, air dried, and cover-slipped 120 
with Fluoroshield (Sigma). Slides were stored in the dark at 4° C. 121 
For single labelling experiments and double labelling of nNOS and NeuN, nNOS was labelled using 122 
rabbit anti-nNOS visualised with Alexa Fluor 488 or 568 goat anti-rabbit secondary. For double 123 
labelling of nNOS and PAN, and nNOS and GABA, nNOS and VGAT, as well as triple labelling of nNOS 124 
with VGLUT1 and VGLUT2, nNOS was labelled with mouse anti-nNOS visualised with Alex Fluor 488 125 
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goat anti-mouse secondary. For the quadruple labelling of nNOS, with PSD95, GluN1 (hereafter 126 
called NMDA-R), and sGC, nNOS was labelled with sheep anti-nNOS visualised with Alexa Fluor 488 127 
donkey anti-sheep. 128 
For each antigen and combination, three sections, collected along the rostral caudal axis of the IC, 129 
from at least four different animals were labelled. Sections processed and incubated with secondary 130 
antibodies in the absence of primary antibody were included as controls.  131 
Image acquisition and analysis 132 
To examine the distribution of labelling throughout the IC, low power (x20) mosaics were acquired 133 
using a Zeiss AxioImager with ZenPro software™. Tiles were stitched during image acquisition and 134 
images were deconvolved using Huygens Essential (SVI)™. To examine the subcellular distribution of 135 
antibody labelling and the proximity of different labels, Z-stacks (Z step 0.1 - 0.3 µm) were acquired 136 
using a 60x oil immersion objective on a Nikon A1+ point scanning confocal microscope with Nikon 137 
Elements software™. The microscope was equipped with four solid state lasers at 405, 488, 561 and 138 
647 nm. Images were acquired at resolution of 1024 pixels in the XY dimension. Z dimensions were 139 
variable. Pixel dimensions were kept at 60 nm for XY with bit depth 12, look up tables (LUTs) were 140 
kept linear and covered the full range of the data collected. Z-stacks for all the required antibody 141 
combinations were acquired from three sections, collected along the rostral caudal axis of the IC, 142 
from at least four different animals. In every section, two Z-stacks were acquired from each region. Z 143 
stacks were deconvolved using Huygens Essential (SVI)™ using a theoretical point spread function 144 
(PSF), automated background estimation, deconvolved with the Classic Maximum Likelihood 145 
Estimation (CMLE) algorithm, quality threshold 0.05 with a maximum number of iterations set at 146 
100. The deconvolved Z-stacks were subsequently analysed using Imaris™ v9.0 (Bitplane.com). To 147 
examine the proximity of the nNOS puncta to puncta labelled for PSD-95, sGC and NMDA-R, all 148 
labelled puncta were first defined using the ‘spot’ function. Around each nNOS spot we created a 149 
sphere of interest with a radius of 0.2 µm. This value was chosen on the basis of the average length 150 
of a postsynaptic density being 0.2-0.8 µm (Sheng and Hoogenraad, 2007). Using the ‘Co-localize-151 
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Spot’ function, we then identified the population of nNOS spots which were in close proximity to at 152 
least one PSD-95 spot (i.e. within the sphere). Next, we determined how many of these nNOS and 153 
PSD-95 containing spheres also contained one or more NMDA-R spots. Finally, we determined how 154 
many of the nNOS/NMDA-R/PSD-95 containing spheres also contained one or more sGC spots. This 155 
allowed us to calculate the proportion of nNOS puncta which were in close proximity to PSD-95 and 156 
NMDA-R and sGC puncta. 157 
To examine the proximity of nNOS puncta to specific subtypes of glutamatergic terminals we first 158 
rendered VGluT1 and VGluT2 labelling using the ‘spot’ function. Next to define populations of 159 
terminals labelled for VGluT1 only, VGluT2 only and for both VGluT1 & 2, we used ‘co-localise spots’ 160 
within a sphere of 0.1 µm. Finally, to determine whether individual nNOS puncta were in close 161 
proximity to the three populations of glutamatergic terminals we used the ‘co-localize spot’ function 162 
and a sphere of 0.6 µm radius around the nNOS punctum as our definition of close proximity. 163 
In vivo electrophysiological recording 164 
Surgical preparation 165 
Animals were anaesthetised with a combination of urethane (1 mg.kg-1 ip, Sigma), fentanyl (0.3 166 
mg.kg-1 ip, Hameln) and midazolam (5mg.kg-1 im, Hameln). Following induction, animals received 167 
supplementary doses of fentanyl as required to prevent a withdrawal response to a hind toe pinch. 168 
Atropine (0.05 mg.kg-1 sc) was also administered to suppress bronchial secretions. A tracheotomy 169 
was performed and the animal was allowed to respire freely in an atmosphere enriched with 170 
medical oxygen, or artificially respired as required with oxygen using a modified small animal 171 
respirator (Harvard Apparatus). The animal was transferred to a sound attenuated room and fixed in 172 
a modified stereotaxic frame (Kopf) equipped with ear bars with Perspex specula positioned to allow 173 
an unobstructed view of the tympanic membrane. The animal’s body temperature was monitored 174 
with a rectal probe and maintained at 38°C with a thermostatically controlled electric heating pad 175 
(Harvard Apparatus). 176 
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A craniotomy was performed over either the left or right IC, and the cerebral cortex overlying the IC 177 
was aspirated. Concentric microdialysis probes (3 mm dialysing window; AN69 Hospal™ membrane) 178 
were manufactured in-house by threading 2 sections of silica fused fibre (ID 110 μm /OD 170 μm, 179 
SGE Analytical Science) through a Y-shaped body constructed of tubular stainless steel (Goodfellow 180 
(AISI 304 (Fe/Cr18/Ni10) diameter 0.5 mm, wall thickness 0.06 mm) glued with Araldite™. A probe 181 
was implanted under visual control into the IC, directed medio-laterally at 10° from the vertical, to a 182 
depth of approximately 4 mm below the surface of the IC. The microdialysis probe was constantly 183 
perfused (2 µl/min) with artificial cerebrospinal fluid (aCSF) (composition (mM) NaCl 140, KCl 3, 184 
Na2HPO4 0.707, NaHPO4 0.272, MgCl2 1, D-glucose 10, and CaCl2 2.4). Microdialysis provided an 185 
effective means of delivering drugs directly into the brain. Because drugs diffuse across the 186 
membrane no mechanical perturbation occurs as the drug is applied (Orton and Rees, 2014). 187 
A recording probe with 32-channels arranged linearly over 3.2 mm (100 µm spacing; Neuronexus 188 
A1x65-10mm-100-177-A32 50) was implanted vertically in the IC immediately rostral to the 189 
microdialysis probe. The depth of the electrode was adjusted to capture responses to the widest 190 
range of sound frequencies based on frequency response areas (Palmer et al., 2013) derived from 191 
the recorded activity. 192 
Sound stimuli and recording 193 
The electrode was connected to a head stage (NN32AC Tucker Davis Technologies (TDT)) connected 194 
to 32 channel preamplifier (PZ2-32, TDT) connected by an optical interface to a BioAmp (RZ2, TDT). 195 
Electrophysiological data were sampled at 24.414 kHz. Multi-unit activity was recorded from all 32 196 
channels in response to pure tones (75 ms duration, 10 ms rise/fall time, total sweep duration 150 197 
ms) at 256, 512, 1024, 2048 and 4096 Hz, presented at nominal levels of 50 and 70 dB sound 198 
pressure level generated by a Multi-I/O Processor (RZ6, TDT) at a sampling rate of 97.656 kHz. Tones 199 
were delivered to the animal with Sony MDR 464 earphones housed in alloy enclosures coupled to 200 
damped probe tubes that fitted into the Perspex specula (Rees, 1990). PSTHs were generated from 201 
multi-unit activity collected over 150 stimulus repeats for each frequency and level. Matlab scripts 202 
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were used to control stimulus presentation, data recording and to store recorded spike data for off-203 
line analysis. 204 
Drug application 205 
Following a baseline period of recording (minimum 1h, beginning at least 1h after implantation of 206 
the electrode) during which aCSF was perfused through the dialysis probe, the perfusate was 207 
switched to aCSF containing one or more drugs (NMDA (Sigma) (30, 100, 300 µM), NG-Methyl-L-208 
arginine (L-MeArg) also known as NG-monomethyl-L-arginine (L-NMMA) (Sigma) (1 mM), 1H-209 
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (Sigma) (500 µM)). To obtain a concentration-210 
response measure for NMDA, increasing concentrations of NMDA were perfused for approximately 211 
40 min, interspersed with intervals of approximately 40 min aCSF (washout). For the L-MeArg and 212 
ODQ experiments, NMDA (100 µM) was perfused for 40 min followed by 40 min aCSF (washout), 213 
then 20 min of L-MeArg or ODQ, then 40 min of NMDA plus L-MeArg or ODQ, 40 min of aCSF, 40 min 214 
of NMDA, and finally 40 min of aCSF. PSTH blocks were generated throughout the periods of 215 
drug/aCSF perfusion.  216 
We based our perfusion times on the temporal and spatial analysis of the effects of lidocaine 217 
infusion by microdialysis reported by Boehnke and Rasmussen (Boehnke and Rasmusson, 2001). We 218 
present data from recordings made 20 min after the onset of drug infusion, the time at which in 219 
Boehnke and Rasmussen’s (2001) analysis drug tissue concentration achieved a maximal and steady 220 
level. Washout data presented are from recordings made 40 min after return to perfusion of aCSF. 221 
Analysis 222 
Off-line electrophysiological recordings from all channels were bandpass filtered with cut-off of 300 223 
Hz and 3000 Hz and thresholded at 2.5 times the standard deviation of the spontaneous activity in 224 
the baseline block collected during sweeps in which the stimulus was maximally attenuated by 225 
120 dB. For all subsequent blocks, ‘activity’ was defined as spikes exceeding this threshold. Data 226 
were analysed from electrode sites best representing each of the five frequencies: 256, 512, 1024, 227 
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2048, and 4096 Hz. For each frequency and level, PSTHs with a binwidth of 1 ms and a duration of 228 
150 ms were constructed from 150 sweeps of thresholded data. The beginning of the sound-driven 229 
response was identified and spikes in a window extending 80 ms from that time were summed to 230 
give the driven response. Driven and spontaneous response rates, measured during the different 231 
drug/washout conditions, were exported to IBM SPSS Statistics V23™ for statistical analysis.  232 
Experimental Design and Statistical Analysis 233 
Immunohistochemistry data cited are descriptive statistics (mean ± SEM (n) where n= number of Z 234 
stacks). Measures were made on two Z stacks per ICC, from each of three sections taken from each 235 
of four animals (24 Z stacks in total).  Z stacks were obtained at x63 magnification with digital zoom 236 
and each one contained between 9 and 15 neuronal somata. 237 
Electrophysiological studies were designed to allow within subjects comparisons.  Multichannel 238 
probes allowed us to gather data from multiple sites in the ICC of individual animals which 239 
corresponded to the best response to each of 5 frequencies.  Responses were determined for each 240 
frequency under different conditions (increasing concentrations of NMDA and washout, or NMDA 241 
with or without L-MeArg or ODQ) in groups of n=3 or n=4 animals.  After testing for sphericity 242 
(Mauchly) the data were analysed using a two way repeated measures ANOVA with ‘frequency’ and 243 
‘drug condition’ as within subject factors. Significant main effects were further analysed using 244 
planned post hoc paired-sample t-tests (two tailed) on relevant comparisons. These were corrected 245 
for multiple comparisons using the Sidak method.   246 
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Results  247 
Two different patterns of nNOS distribution in the IC 248 
To elucidate the functional properties of NO in the IC, we first examined the regional, cellular, and 249 
subcellular distribution of its synthetic enzyme, nNOS in the guinea pig (Cavia porcellus) IC using 250 
fluorescence immunohistochemistry. At low magnification, abundant expression of nNOS is 251 
apparent in the ICD and ICL, but little or no expression is visible in the ICC (Fig 1a). Many neurons are 252 
visible in the ICD and ICL which have nNOS distributed diffusely throughout the cytoplasm of their 253 
somata and dendrites (Fig 1b & c). However, at high magnification, scattered among these 254 
cytoplasmically labelled neurons (Fig 1c), we observed bright spots of nNOS labelling (Fig 1c) that we 255 
dubbed ‘nNOS puncta’. The discovery of nNOS puncta prompted us to look more closely at the ICC - a 256 
region devoid of cytoplasmically labelled nNOS neurons. Here, again under high magnification, many 257 
nNOS puncta (0.4-0.8 µm in diameter) were visible, clustered around nuclei apparently outlining cell 258 
somata (Fig 1d). Double labelling for nNOS and the neuronal marker NeuN showed that these cells 259 
were neurons and also revealed, surprisingly, that the somata of apparently all neurons in the ICC 260 
contain nNOS puncta (Fig 1ei & eii). Double labelling for nNOS and Neurochrom (a pan-neuronal 261 
antibody cocktail labelling somatic, nuclear, dendritic, and axonal proteins) indicated that all nNOS 262 
puncta are neuronal and that they occur within other neuronal elements as well as somata (Fig 1f 263 
& g).  264 
To determine the neurotransmitter phenotype of neurons containing nNOS puncta, we performed 
double labelling with antibodies for nNOS and GABA. In the ICD and ICL (Fig 1h) as well as in the ICC 
(Fig 1i), nNOS expression was observed in both GABA positive (Fig 1h & i, open arrows) and GABA 
negative neurons. Since virtually all IC neurons are either glutamatergic or GABAergic (Oliver et al., 
1994; Merchán et al., 2005), GABA negative neurons are likely to be glutamatergic (Fig 1h & i, filled 
arrows). 
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Figure 1  
nNOS expression occurs in all subdivisions of the inferior 
colliculus. a) mosaic image of a 40 µm coronal IC section 
labelled for nNOS (green). nNOS can be seen densely 
expressed in the dorsal cortex (ICD) and lateral cortex 
(ICL), while expression is apparently absent from most of 
the central nucleus (ICC). b) in the ICD there are many 
neurons with nNOS distributed diffusely throughout their 
cytoplasm (open arrows). However, puncta of nNOS 
(closed arrow) surrounding a DAPI stained nucleus (blue) 
can also be observed in this region. c) in the ICL, large 
neurons with extensive dendrites completely filled with 
nNOS are visible (open arrow). Again, however, puncta 
of nNOS (closed arrow) surrounding a DAPI stained 
nucleus (blue) can also be observed in this region d) 
Although the ICC appears devoid of nNOS at low 
magnification, at higher magnification puncta of nNOS 
surrounding DAPI stained nuclei are revealed. e) In the 
ICC, virtually all neurons, visualised by NeuN (ei 
(magenta)), show signs of punctate nNOS expression (eii 
(green)): in eii dotted lines outline cell somata visualised 
by NeuN labelling. f) dual immunohistochemistry for 
nNOS (green) and a pan neuronal antibody cocktail (PAN, 
magenta) shows that nNOS labelled puncta are present 
on the membrane of both somata and dendrites. g) 
Rendering in Imaris shows clearly how nNOS puncta 
(green spots) are localised on neuronal elements 
(magenta surfaces). h) In the ICD, dual 
immunohistochemistry for nNOS (green) and GABA 
(blue) rendered in Imaris shows that some nNOS filled 
cells contain GABA (open arrow), whilst others are GABA 
negative (closed arrow) and are presumed to be 
glutamatergic. Note the GABA labelling (asterisks) on the 
glutamate neuron shown here (closed arrow) is 
restricted to the surface and therefore considered to be 
terminals. In contrast, the GABAergic neuron (open 
arrow) shows GABA labelling throughout its cytoplasm. 
i) In the ICC, Imaris rendering shows that some cells in the 
ICC with nNOS puncta (green) also contain GABA (blue, 
open arrow), while others that do not (closed arrow) and 
are presumed to be glutamatergic. CoIC: intercollicullar 
commissure; Aqueduct: aqueduct of Sylvius. Scale bars 
are 10 µm, except part a) 500 µm.  
 
15 
Punctate nNOS is structurally associated with PSD95, the NMDA receptor, and sGC. 265 
In the ICC we observed nNOS puncta at the neuronal membrane. We reasoned that, if they occur in 266 
close proximity to NMDA receptors and sGC, they could be involved in NMDA receptor 267 
neurotransmission. We used high resolution confocal microscopy and image analysis to visualise 268 
quadruple immunofluorescence labelling for nNOS, GluN1 (the obligatory subunit of the NMDA 269 
receptor), and sGC α2β1 (hereafter sGC), together with PSD95.  270 
Dense, punctate labelling for PSD95 and NMDA-R was found throughout the ICC. Both punctate and 271 
diffuse sGC labelling could also be seen within ICC neurons. High resolution confocal imaging 272 
revealed considerable overlap between the subcellular distribution of the nNOS puncta (Fig 2ai) and 273 
labelling for PSD95 (Fig 2bi), NMDA-R (Fig 2ci), and sGC (Fig 2di). To verify the association between 274 
these proteins, their puncta were first rendered to ‘spots’ using Imaris™ (Fig 2aii-dii). We then, 275 
created a sphere of interest, 0.2 µm in diameter, around the centre of each nNOS spot, and 276 
determined whether spots for PSD95, NMDA-R and sGC occurred within this sphere (Fig 2e). 277 
Almost all (92 ± 4 %) of the spheres around nNOS puncta contained labelling for PSD95, and NMDA-R 278 
and sGC, demonstrating that nNOS puncta almost always occur in proximity to NMDA, sGC and 279 
PSD95 (Fig 2f & g). Interestingly, this analysis revealed a highly consistent order of labelling within 280 
the spheres with nNOS and NMDA-R sandwiched between sGC and PSD95 (Fig 2f & g). This 281 
consistency suggests that the four protein elements occur in a fixed structural arrangement.  282 
To estimate the extent to which NMDA neurotransmission in the ICC is mediated by NO, we also 283 
determined the proportion of the total NMDA-R spots in the ICC that are associated with nNOS. On 284 
neuronal somata in the ICC, 84 % (± 5 %) of the NMDA-R spots were associated with nNOS spots. 285 
However, at non-somatic sites, presumably dendrites, only 19% (± 6 %) of NMDA-R spots were 286 
associated with nNOS spots.  287 
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Figure 2  
nNOS puncta in the IC are in close proximity to puncta labelled for PSD95, NMDA-R and sGC. ai) A cell soma in the ICC showing 
nNOS puncta (green). bi) the same cell also contains PSD-95 (magenta), ci) the NMDA-R (blue), and di) sGC (red). In aii), bii) 
cii) and dii) labelled puncta in the raw images ai-di have been rendered to ‘spots’ in Imaris. e) illustrates how we determined 
whether individual nNOS puncta were in close proximity to puncta labelled for PSD95, NMDA-R and sGC. A sphere of 0.2 µM 
radius was centred on each nNOS spot, and the occurrence of PSD95, NMDA-R and sGC spots within this sphere was 
determined. f) Ellipsoids (shown for the box in aii-dii) are coloured to show the occurrence of the four proteins within the 0.2 
µm sphere of interest. Virtually all nNOS spots are in close proximity to spots representing PSD-95, NMDA, and sGC. Note, 
even where only three colours are seen in this 2D view (cluster marked by *), when the vantage point is changed (g) the fourth 
colour can be seen. Scale bars in a-d are 10µm, f and g are 1 µm.  
 
288 
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nNOS puncta are postsynaptic to glutamatergic terminals 289 
The association of nNOS puncta with NMDA-R suggests they occur at glutamatergic synapses. To test 290 
this prediction we determined whether nNOS puncta are associated with labelling for the VGluT1 291 
and VGluT2 subtypes of the presynaptic-terminal vesicular glutamate transporter. To exclude the 292 
association of nNOS with GABA and glycine terminals, we also used an antibody against VGAT- the 293 
GABA and glycine vesicular transporter. 294 
Confocal imaging and image analysis using Imaris™ revealed three populations of presumed 295 
glutamatergic terminals in the ICC: some terminals had labelling for VGluT1 only, others labelled for 296 
VGluT2 only, and a third population had labelling for both VGluT1 and VGluT2 within the same 297 
terminal. We classified a terminal as ‘VGluT1 & 2’ when VGluT1 and VGluT2 spots occurred within 298 
0.1 µm of each other.  299 
We saw all three patterns of labelling around neurons containing nNOS puncta in the ICC (Fig 3a). 300 
VGluT2 only terminals were particularly abundant, but nNOS spots were rarely close to these 301 
terminals (only 3 ± 3 % were within a 0.6 µm diameter sphere). VGluT1 only terminals were less 302 
abundant and again nNOS spots were rarely close to them (only 5 ± 2 % were within a 0.6 µm 303 
diameter sphere). Although many VGluT1 & 2 terminals were not associated with nNOS puncta, 304 
intriguingly, almost all nNOS puncta (89 ± 3 %) coincided with terminals labelling for VGluT1 & 2 (Fig 305 
3cii, dii & eii). Many neurons expressing nNOS puncta also had VGAT labelled terminals around them 306 
(Fig 3b). However, proximity testing in Imaris™ never showed any association between puncta 307 
labelled for nNOS and VGAT.  308 
These findings provide evidence that nNOS puncta in the ICC are associated with NMDA receptors, 309 
sGC and PSD95, and occur at glutamatergic synapses with presynaptic terminals of fibres expressing 310 
both VGluT1 & 2. 311 
 312 
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Figure 3  
nNOS puncta in the IC are innervated by glutamatergic terminals which predominantly contain both VGluT1 and VGlutT2. a) 
Imaris rendering of a neuron containing nNOS puncta (omitted for clarity) in the ICC showing the distribution of terminals 
containing VGluT1 only (cyan), VGluT2 only (magenta) and VGluT1 & 2 (white). Note: this neuron receives a substantial 
number of terminals labelling for VGluT2 only (magenta), a smaller number of terminals labelling for VGluT1 & 2 (white), 
while terminals labelling for VGluT1 only (cyan) are infrequent. b) Imaris rendering of a cell in the ICC with 
GABAergic/glycinergic terminals containing VGAT (blue), and nNOS puncta (green). Note: this cell receives 
GABAergic/glycinergic terminals, but there is no correspondence between these and the nNOS puncta. ci-ei) A slice from a Z-
stack showing a neuron from the ICC. Labelling for ci) VGluT1 (cyan); di) VGluT2 (magenta) and ei) nNOS (green). cii-eii) The 
Z-stacks containing the images in ci-ei were rendered to ‘spots’ in Imaris representing glutamatergic terminals that contain 
cii) VGluT1 (cyan) and dii) VGluT2 (magenta). Note almost all the glutamatergic terminals on this cell contain both VGluT1 
and VGluT2 as confirmed in eii where terminals labelling for VGluT1 & 2 are shown as white spots. eii also shows that the 
white spots (VGluT1 & 2 terminals) form ellipsoids with the green spots (nNOS puncta) indicating that they are in close 
proximity to each other. DAPI stained nuclei are shown in grey. Scale bars in a and b, 10 µm, c-e, 2 µm.  
313 
19 
nNOS puncta in the ICC are functional and mediate the effects of NMDA receptor activation  314 
Our immunohistochemical studies demonstrated that punctate nNOS forms a multi-protein complex 315 
with NMDA-R and sGC, anchored to PSD95. This suggests that stimulation of these NMDA receptors 316 
should lead to the production of NO, which in turn should activate its receptor, sGC to produce 317 
cGMP. If this is the case, then inhibition of nNOS or sGC might modulate neuronal responses to 318 
NMDA in the ICC. To test this prediction, we conducted electrophysiological recordings in the ICC. 319 
In anaesthetised guinea pigs we used multi-site electrodes to record neuronal activity along the 320 
tonotopic axis of the ICC in response to sound. Simultaneously, we delivered drugs targeting NMDA 321 
receptors, nNOS, and sGC in the vicinity of the electrodes using microdialysis (Fig 4a, see Methods). 322 
Pure tone stimuli (75 ms in duration) were presented at frequencies of 256, 512, 1024, 2048 and 323 
4096 Hz. Peri-stimulus time histograms (PSTHs), constructed from multiunit activity recorded at the 324 
five electrode positions maximally activated by these five frequencies, (Fig 4b), typically showed a 325 
marked increase in firing with a latency of about 10 ms corresponding to the onset of the tone, 326 
followed by a sustained, lower elevation in firing for the remainder of the tone duration.  327 
First we demonstrated that NMDA delivered to the ICC influences sound-driven responses in a 328 
concentration dependent manner. After a baseline recording during which artificial cerebrospinal 329 
fluid (aCSF) alone was perfused (Fig 4bi), we delivered NMDA in increasing concentrations (30, 100 330 
and 300 µM) (Fig 4bii, iv, & vi) with a washout period of aCSF between each drug application (Fig 331 
4biii, v & vii). As the concentration of NMDA was increased, there was a concomitant increase in the 332 
sound-driven activity recorded at all frequency locations (Fig 4c and Table 1). The effect of NMDA 333 
was maximal after 20 min, and progressively reversed over the course of 40-50 min during which the 334 
NMDA was washed out, although reversal was incomplete after the highest concentration of NMDA 335 
(Fig 4bvii & 4c). NMDA also increased spontaneous activity in a concentration-dependent manner 336 
(Table 1, see also the 10 ms pre-response period in Fig 4bii, iv & vi). Note, however, that 337 
spontaneous activity was 5-10 times below the level of sound-driven activity (Table 1).  338 
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Figure 4  
NMDA receptor activation increases sound-driven activity in the ICC in a concentration-dependent and reversible manner. a) 
Above, anaesthetised guinea pigs were implanted with a microdialysis probe and a 32-channel linear recording probe; sound 
stimuli were delivered to the ears through a closed acoustic system.  Below, schematic coronal section through the IC showing 
the relative positions of the microdialysis probe and the electrode in the ICC. bi-bvii) Example PSTHs of responses to 1024 Hz 
tone-burst (75 ms duration) during baseline (bi, aCSF) and local perfusion of NMDA at three different concentrations (bii, 30; 
biv, 100; & bvi, 300 µM) with aCSF washouts (biii, bv, & bvii). Note: the peak of activity at the onset of the sound stimulus and 
the lower sustained activity during the remainder of the stimulus. NMDA increased the response throughout the stimulus in 
a concentration dependent manner. c) Group data derived from PSTHs (as in b) revealing local application of NMDA increased 
sound-driven activity recorded from all of the individual electrode sites with the greatest responses to 256, 512, 1024, 2048 
and 4096 Hz. NMDA (30, 100 and 300 µM) increased the response in a concentration-dependent manner at all frequencies, 
and this effect partially reversed on washout. Data show firing recorded 20 minutes after the start of NMDA perfusion, and 
for the washout blocks, 40 min after perfusion of aCSF. n = 3 animals. *p<0.05; ***p<0.001 paired sample t-test planned post 
hoc comparison, Sidak corrected for multiple comparisons, following significant ANOVA. Boxplots show median and 
interquartile range, together with individual data points.  
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Table 1. Effect of increasing concentrations of NMDA on spontaneous and sound-driven activity. 
Spontaneous and sound-driven firing rates for each frequency in ICC during perfusion of increasing concentrations of NMDA, 
or washout with aCSF. The sequence in each column follows the order in Fig 4b. The values are the mean ± SEM of the 
multiunit firing rate (spikes.s-1) during each stimulus presentation averaged across animals (n=3).   
 
 
 
256 Hz 512 Hz 1024 Hz  
spontaneous driven spontaneous driven spontaneous driven 
aCSF  6.6 ± 1.9  46.2 ± 28.1  6.8 ± 0.3  48.4 ± 22.6  7.3 ± 0.9  49.9 ± 39.6 
30 µM NMDA  7.5 ± 4.1  62.4 ± 36.3  7.8 ± 3.5  93.7 ± 48.5  10.1 ± 3.0  82.6 ± 69.5 
aCSF  8.7 ± 5.7  66.1 ± 43.4  8.1 ± 2.5  65.0 ± 32.6  8.9 ± 1.9  66.7 ± 59.9 
100 µM NMDA 14.6 ± 7.0  92.4 ± 49.0  12.3 ± 1.9  118.4 ± 57.5  15.6 ± 2.9  125.2 ± 94.9 
aCSF 10.3 ± 4.9  68.2 ± 35.4  6.8 ± 2.2  72.8 ± 41.5  11.1 ± 3.3  81.2 ± 77.7 
300 µM NMDA 23.0 ± 12.0 135.4 ± 76.9  16.7 ± 3.3  159.8 ± 76.1  21.8 ± 8.0  131.6 ± 96.3 
aCSF 18.5 ± 16.5  94.2 ± 54.7  9.5 ± 2.0  113.0 ± 66.2  13.7 ± 2.2  106.8 ± 97.0 
 
 
2048 Hz 4096 Hz  
spontaneous driven spontaneous driven 
aCSF  7.8 ± 3.4  63.6 ± 35.1  6.7 ± 4.1  55.9 ± 20.5 
30 µM NMDA  12.1 ± 6.6  86.1 ± 46.9  9.1 ± 6.8  68.9 ± 30.7 
aCSF  12.9 ± 6.6  85.0 ± 47.4  13.7 ± 12.8  69.8 ± 26.5 
100 µM NMDA  18.8 ± 10.3  142.6 ± 91.9  16.5 ± 10.3  117.5 ± 54.8 
aCSF  13.0 ± 8.8  100.5 ± 44.9  10.6 ± 6.7  79.7 ± 22.7 
300 µM NMDA  25.5 ± 16.2  157.8 ± 106.8  19.6 ± 10.7  136.9 ± 72.7 
aCSF  17.3 ± 10.8  110.7 ± 44.7  13.4 ± 7.6  105.8 ± 46.9 
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Subjecting the data shown in Fig 4c to a two way repeated measures ANOVA revealed a significant 340 
main effect of drug condition (F6,12=131.2, p<0.0001), but no main effect of frequency (F4,8=1.4, n.s.), 341 
and no significant condition x frequency interaction (F24,48=1.1, n.s.). Activity levels induced by all 342 
concentrations of NMDA were significantly different from baseline (average across all frequencies, 343 
percent of baseline ± SEM: 30 µM, 148 ± 3.9 %, p=0.018; 100 µM, 225.5 ± 10.1 %, p=0.018; 300 µM, 344 
275.4 ± 2.1 %, p=0.0003. Post hoc t-test with Sidak correction for multiple comparisons). 345 
NMDA-evoked activation of the ICC is mediated by nNOS 346 
To test whether the NMDA-evoked increase in sound-driven activity seen in the previous experiment 347 
is mediated by NO, we combined perfusion of NMDA with perfusion of the reversible nNOS inhibitor 348 
L-MeArg. Based on the previous experiment, we chose an NMDA concentration of 100 µM for this, 349 
since it elicited a robust and readily reversible increase in sound-driven activity. 350 
As before, NMDA (100 µM) evoked an increase in sound-driven activity at all frequencies (Fig 5aii & 351 
5b), and this reversed during washout (Fig 5b). Next we applied L-MeArg (1 mM) immediately 352 
followed by L-MeArg (1mM) in combination with NMDA (100 µM). In the presence of L-MeArg alone, 353 
sound-driven activity was unaffected at any of the frequencies tested (Fig 5b). Remarkably, when 354 
L-MeArg was applied along with NMDA, NMDA failed to elicit any increase in firing (Fig 5aiii & b). To 355 
verify that neurons were still capable of responding to NMDA after L-MeArg washed out, we 356 
perfused NMDA (100 µM) alone. Again we observed the expected large increase in sound-driven 357 
activity (Fig 5aiv).  358 
Two way repeated measures ANOVA confirmed a significant main effect of drug condition 359 
(F7,21=17.6, p<0.0001), but no significant main effect of frequency (F4,12=1.4, n.s.), and no significant 360 
condition x frequency interaction (F28,84=2.1, n.s.). Post hoc t-tests, Sidak corrected, showed that 361 
both the initial and final NMDA-alone conditions, averaged across all frequencies, were significantly 362 
different from baseline (217.0 ± 16.3 %, p=0.022 and 231.7 ± 7.01 %, p=0.0013, respectively), while  363 
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Figure 5  
The effect of NMDA is blocked by the inhibition of nNOS and sGC. a) Example PSTHs of the response to 1024 Hz tone-bursts 
during (ai) baseline (aCSF) and perfusion of (aii) NMDA (100 µM) and (aiii) NMDA combined with L-MeArg (1mM). Washout 
and L-MeArg alone blocks are not shown. Note: (aiii) NMDA fails to increase sound-driven activity in the presence of 
L-MeArg, but (aiv) its effect is restored after washout of L-MeArg. b) Group data (n=4) derived from PSTHs (as in a) for all 
frequencies. Perfusion of NMDA (100 µM) increased sound-driven activity at all frequencies. L-MeArg alone had no effect on 
sound-driven activity, but blocked the response to NMDA. Following washout of L-MeArg, NMDA again increased sound-
driven activity. c) Example PSTHs of response to 1024 Hz tone-bursts during (ci) baseline (aCSF) and perfusion of (cii) NMDA 
(100 µM) and (ciii) NMDA combined with the sGC inhibitor ODQ (500 µM). Washout and ODQ-alone blocks are not shown. 
Note: (ciii) NMDA fails to increase sound-driven activity in the presence of ODQ, but (civ) its effect is restored after washout 
of ODQ. d) Group data (n=3) derived from PSTHs (as in c) for all frequencies. Perfusion of NMDA (100 µM) increased the 
sound-driven activity at all frequencies. ODQ alone had no effect, but blocked the response to NMDA. Following washout of 
ODQ, NMDA again increased sound-driven activity. Data show firing recorded 20 minutes after the start of drug perfusion, 
or 40 min after the start of aCSF perfusion. *p<0.05; **p < 0.01 paired sample t-test planned post hoc comparison, Sidak 
corrected for multiple comparisons, following significant ANOVA. Boxplots show median and interquartile range, together 
with individual data points. 
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the L-MeArg alone and L-MeArg plus NMDA conditions were not significantly different from baseline 364 
(103.5 ± 19.1 % n.s. and 95.8 ± 17.5 % n.s., respectively). 365 
These data are consistent with our hypothesis that modulation of sound-driven activity by the 366 
activation of NMDA receptors in the ICC is mediated by the stimulation nNOS leading to the synthesis 367 
of NO. 368 
NMDA-evoked activation of the ICC is mediated by sGC 369 
Finally we addressed whether the nNOS dependent response to NMDA observed above also requires 370 
the activation of sGC. To examine this, we combined application of NMDA with perfusion of the sGC 371 
inhibitor ODQ. Initial perfusion of NMDA (100 µM) evoked an increase in sound-driven activity (Fig 372 
5cii & f) which reversed on washout. Next we perfused ODQ (500 µM) alone (Fig 5d) before 373 
perfusing NMDA in combination with ODQ (Fig 5d). Sound-driven activity was unaffected with ODQ 374 
alone (Fig 5d), and when ODQ was applied along with NMDA, NMDA failed to elicit any increase in 375 
firing (Fig 5ciii & f). Finally, following ODQ washout, a further perfusion of NMDA alone elicited the 376 
expected large increase in sound-driven activity (Fig 5civ & d). 377 
A two way repeated measures ANOVA confirmed a significant main effect of drug condition 378 
(F7,14=21.4, p<0.0001), no significant main effect of frequency (F4,8=3.8, n.s.), and no significant 379 
condition x frequency interaction (F28,56=1.1, n.s.). Post hoc t-tests, Sidak corrected, showed that 380 
both the initial and the final NMDA-alone conditions, averaged across all frequencies, were 381 
significantly different from baseline (232.5 ± 14.9 % p=0.050 and 231.2 ± 12.4 %, p=0.035 382 
respectively), while the ODQ alone and ODQ with NMDA conditions were not significantly different 383 
from baseline (113.0 ± 14.9 %, n.s., and 110.8 ± 8.8 %, n.s. respectively).  384 
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Discussion       385 
Here we report punctate expression of nNOS in the IC and demonstrate its functional involvement in 386 
auditory processing in vivo. nNOS expression in the IC is more extensive than previously reported: in 387 
addition to cytoplasmically labelled nNOS neurons in the IC cortices, nNOS also occurs in the ICc 388 
where it is in the form of puncta. Virtually all these nNOS puncta are associated with NMDA-R, sGC, 389 
and PSD95, and apposed to glutamatergic terminals suggesting a postsynaptic multi-protein complex 390 
that mediates NMDA-R signalling through the production of NO. The importance of NMDA-receptor 391 
and NO signalling in ICC is revealed by in vivo experiments that demonstrate the increase in sound-392 
driven neuronal firing by NMDA is completely inhibited by blockade of either nNOS or sGC.  393 
Two distinct patterns of nNOS in the IC 394 
The nNOS expression we report in the cortices of the IC concurs with previous studies showing 395 
neurons with diffuse cytoplasmic labelling, are abundant in these subdivisions (Herbert et al., 1991; 396 
Druga and Syka, 1993; Coote and Rees, 2008; Hinova-Palova et al., 2017). However, we find nNOS 397 
puncta in neurons located in all three subdivisions of the IC. Importantly, vast numbers of nNOS 398 
puncta are found in the ICC, indeed virtually all neurons in the ICC, both glutamatergic and 399 
GABAergic, contain nNOS puncta. The ubiquitous presence of nNOS in neurons in the ICC may 400 
previously have gone unnoticed because it occurs in the form of puncta not visible at low 401 
magnification.  Interestingly, a recent paper addressing developmental changes in mouse brain 402 
included a low power image in which punctate nNOS labelling in the ICC is apparent (Fujimoto et al., 403 
2017), although this was not noted or discussed. 404 
nNOS puncta are structurally associated with PSD95 and with NMDA-R and sGC  405 
In several brain regions, the NMDA receptor has been linked to NO signalling. Given that Ca2+ ion 406 
entry via NMDA receptors is highly localised, and that NO is only synthesised in pico molar 407 
concentrations, it has been postulated that the proteins in this pathway must be in close proximity 408 
(Garthwaite, 2008). Previous studies (Kornau et al., 1995; Brenman et al., 1996; Niethammer et al., 409 
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1996; Russwurm et al., 2001) show that nNOS, NMDA-R and sGC can all potentially interact with 410 
PSD95. Until now, however, the formation of a multi-protein complex involving all four proteins had 411 
not been demonstrated in native tissue. Using quadruple immunohistochemistry, we revealed that 412 
virtually all nNOS puncta in the ICC occur close to PSD95, NMDA-R and sGC, confirming that nNOS in 413 
the IC exists as part of this multi-protein complex. To the best of our knowledge, this is the first time 414 
all four proteins have been demonstrated to occur simultaneously at the same postsynaptic site, as 415 
illustrated schematically in Fig 6.  416 
In contrast, neurons with cytoplasmic labelling for nNOS in the cortices of the IC, are not associated 417 
with the proteins that constitute the multi-protein complex at nNOS puncta. This suggests a less 418 
temporally- and spatially-specific mode of action of NO in these neurons, perhaps by volume 419 
transmission, as has been shown to occur elsewhere in the auditory pathway (Steinert et al., 2008). 420 
nNOS puncta are innervated by glutamatergic terminals 421 
We found that nNOS puncta at the cell membrane of neurons occur in close apposition to 422 
glutamatergic terminals, indicating that they are situated in synapses and likely to be functionally 423 
active. A previous report showed punctate nNOS in the hippocampus located on dendritic spines 424 
receiving glutamatergic inputs (Burette et al., 2002), as well as occasionally bound to the post 425 
synaptic densities of GABAergic synapses (Szabadits et al., 2007). In the IC, we found nNOS puncta 426 
are almost exclusively associated with glutamatergic presynaptic terminals identified by the 427 
presence of vesicular glutamate transporter proteins (Fremeau et al., 2001; Kaneko and Fujiyama, 428 
2002), and never with GABAergic or glycinergic terminals.  429 
The expression of VGluT1 and VGluT2 in the terminals of fibres in the ICC helps reveal their origin (Ito 430 
and Oliver, 2010; Ito et al., 2011). Thus, terminals containing exclusively VGluT1 originate 431 
predominantly from the cerebral cortex, whereas terminals containing only VGluT2, represent intra-432 
collicular connections, along with ascending inputs from the dorsal cochlear nucleus, some nuclei in 433 
the superior olive and the lateral lemniscus (Ito and Oliver, 2010). Terminals containing both VGluT1  434 
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Figure 6 
Schematic representation of NO signalling mediating NMDA receptor activation in the central nucleus of the IC. A presynaptic 
glutamatergic terminal containing both VGluT1 & 2 is in close apposition to a postsynaptic multi-protein complex consisting 
of NMDA-R, nNOS and sGC, attached to the scaffold protein PSD95. Initial depolarisation by glutamate binding to AMPA 
receptor, allows the activation of the NMDA receptor. Calcium ions enter the cell through the NMDA receptor and activate 
nNOS (via calmodulin not shown) leading to the synthesis of NO. NO in turn activates sGC which produces the second 
messenger cGMP. Other excitatory and inhibitory terminals not terminating on NOSergic multi-protein complexes are shown. 
Note also the presence of a separate pool of NMDA receptors not linked to the NO signalling pathway. 
435 
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& VGluT2 belong to fibres originating from three principal sources in the brainstem: the contralateral 436 
ventral cochlear nucleus (VCN), the ipsilateral medial superior olivary nucleus (MSO), and certain 437 
subdivisions of the periolivary nuclei (Ito and Oliver, 2010).  438 
We cannot specify the sources giving rise to the VGluT1 & 2 terminals associated with the nNOS 439 
puncta, and there are indeed many VGluT1 & 2 terminals that are not associated with nNOS puncta. 440 
However, it seems unlikely that precisely timed inputs from the MSO, (which signal interaural time 441 
differences (Grothe et al., 2010)), would terminate at synapses with ‘slowly’ responding NMDA 442 
receptors. More likely these terminals originate from the Type 1 multipolar (or T stellate) neurons in 443 
the VCN (Cant and Benson, 2003; Cant and Benson, 2006) which signal information about the 444 
spectrum of sounds (Young et al., 1988; Blackburn and Sachs, 1989, 1990; Oertel et al., 2011). If Type 445 
1 multipolar neurons signal through NMDA receptors in the ICC, they could mediate some form of 446 
neuronal plasticity. 447 
Potential physiological role of nNOS/sGC signalling in the ICC 448 
Our electrophysiological data show the important influence NO signalling can have in the ICC. Local 449 
perfusion of NMDA in the ICC resulted in a substantial and concentration-dependent increase in 450 
sound-driven activity. Remarkably, this NMDA-evoked increase in activity was completely blocked 451 
when we inhibited nNOS or sGC.  These effects are likely to originate in the ICC since substances 452 
infused by microdialysis are spatially limited to ~1.5 mm from the probe Boehnke and Rasmussen 453 
(Boehnke and Rasmusson, 2001). Furthermore, since neurons in the IC cortices do not project back 454 
to the ICC, indirect effects from those subdivisions are unlikely. 455 
Sound stimuli drive neuronal activity in the ICC via multiple parallel excitatory and inhibitory inputs 456 
(Oliver, 2005). Glutamatergic inputs have been shown to be mediated by both AMPA and NMDA 457 
receptors (Faingold et al., 1989; Zhang and Kelly, 2001) and it is perhaps surprising, that blocking 458 
nNOS and sGC had no effect on endogenous glutamatergic signalling in response to sound. Prosaic 459 
reasons, relating to the time course and concentration of drug application or sensitivity of our 460 
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measure, could explain this finding, but it is interesting that with a different method in a different 461 
structure, Yassin et al (2014) similarly found no effect of ODQ when it was applied alone.  462 
It should be noted that while most NMDA receptors on the somata are linked to nNOS, we found 463 
many NMDA receptors, particularly on the dendrites, which were not linked to nNOS. The influence 464 
of the latter population on sound-driven activity should not be blocked by L-MeArg or ODQ. Thus 465 
these two populations of NMDA receptors may be activated under different conditions and serve 466 
different functions. 467 
A role for NMDA receptors and nNOS in adaptive and maladaptive changes? 468 
The modulation of neuronal signalling in the ICC through the activation of NMDA receptors and 469 
nNOS , suggests the these mechanisms may mediate adaptive or plastic changes in response to 470 
sound (Slee and David, 2015). The auditory system is highly plastic and evidence suggests that the IC 471 
is particularly so (Yan and Suga, 1998; Suga and Ma, 2003). Sustained NMDA receptor activation 472 
subsequent to stimulus or neuromodulatory input will activate nNOS and lead to production of 473 
cGMP. Via protein Kinase G, cGMP induces phosphorylation of AMPA receptor subunits and thereby 474 
influences the insertion of AMPA receptors into the cell membrane (Serulle et al., 2007; Incontro et 475 
al., 2013; Song et al., 2016). This mechanism would enhance neuronal excitability and might underlie 476 
the increase in sound-driven activity we observed following NMDA perfusion. In some 477 
circumstances, changes in nNOS expression may be maladaptative. Thus increases in neuronal 478 
excitability and firing occur in the IC following acoustic trauma (Mulders and Robertson, 2009) or 479 
salicylate (Patel and Zhang, 2014; Olthof-Bakker et al., 2017). These changes could depend on the 480 
upregulation of nNOS, as has been demonstrated in the cochlear nucleus in similar animal models of 481 
tinnitus (Zheng et al., 2006; Coomber et al., 2015).  482 
Wider implications 483 
The discovery of extensive punctate nNOS expression in the ICC has important implications for our 484 
understanding of neuronal mechanisms of sound processing in the IC and the auditory pathway. But 485 
30 
these findings also have implications beyond the auditory system. The discovery of nNOS puncta in a 486 
region previously thought to be devoid of nNOS highlights the fact that nNOS expression, and by 487 
extension NO signalling, may have gone unnoticed in other brain regions. Our finding of two distinct 488 
subcellular distributions may lead to a new understanding of how NO contributes to neuronal 489 
processing.  490 
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